By South China Morning Post | Created at 2024-11-22 08:16:16 | Updated at 2024-11-22 13:55:55
5 hours ago
1. HIV cure on horizon? Hong Kong firm Immuno Cure unveils promising vaccine, ICVAX
“We may be on the brink of a breakthrough,” the company advisory board chairman said as the biotech start-up reported promising results from clinical trials. The vaccine, designed to be administered after infection, could offer a potential cure for HIV, the virus that causes Aids.
2. Trump tariffs threaten Chinese biotech profits, medical device makers brace for impact
Chinese biotech firms are facing a double whammy of US funding restrictions and tariffs after Trump proposed import duties of 60 to 100 per cent on Chinese goods. Efforts to expand high-value product sales within China and alternative overseas markets outside the US may mitigate the impact.
3. China’s pharmaceutical boom sees market surge past US$13 billion with 113 new drugs since 2021
China’s pharmaceutical industry is booming, with 113 innovative drugs approved since its 14th five-year plan began in 2021, exceeding the previous five-year plan by nearly three times. This surge in innovation has driven the market scale to US$13.8 billion, making China a global leader in drug development.
